Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced Monday that its Board of Directors has approved a stock repurchase program. The company is authorized to buy back up to $50 million of its common stock by March 27, 2026.
The repurchase plan is part of Emergent’s broader multi-year transformation strategy aimed at driving growth and profitability. President and CEO Joe Papa expressed the company’s belief in its strategic direction and its ability to generate cash as key reasons for the buyback, emphasizing the goal of creating value for shareholders. The company’s financial position appears solid, with a current ratio of 3.69 indicating strong liquidity, while analysts expect net income growth this year.
The repurchase of shares will be conducted on the open market or through privately negotiated transactions, subject to market conditions and other factors. Management will decide the timing and volume of repurchases, adhering to the company’s insider trading policy. Emergent reserves the right to suspend or discontinue the repurchase program at any time.
As of December 31, 2024, Emergent had approximately 54.3 million shares of common stock outstanding. The company focuses on developing treatments for serious health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.